These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 2862135)

  • 1. Screening for cognitive toxicity of anticholinergic drugs.
    Katz IR; Greenberg WM; Barr GA; Garbarino C; Buckley P; Smith D
    J Clin Psychiatry; 1985 Aug; 46(8):323-6. PubMed ID: 2862135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relation of serum anticholinergicity to cognitive status in schizophrenia patients taking clozapine or risperidone.
    Tracy JI; Monaco CA; Abraham G; Josiassen RC; Pollock BG
    J Clin Psychiatry; 1998 Apr; 59(4):184-8. PubMed ID: 9590669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Plasma anticholinergic activity and cognitive function in geriatric patients].
    Thienhaus OJ; Thoene J; Allen A; Zemlan FP
    Psychiatr Neurol Med Psychol (Leipz); 1990 May; 42(5):275-81. PubMed ID: 1975100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients.
    Tune LE; Strauss ME; Lew MF; Breitlinger E; Coyle JT
    Am J Psychiatry; 1982 Nov; 139(11):1460-2. PubMed ID: 6127957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of low serum anticholinergic levels and cognitive impairment in elderly presurgical patients.
    Miller PS; Richardson JS; Jyu CA; Lemay JS; Hiscock M; Keegan DL
    Am J Psychiatry; 1988 Mar; 145(3):342-5. PubMed ID: 3344848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.
    Akdede BB; Anil Yağcioğlu AE; Alptekin K; Turgut TI; Tümüklü M; Yazici MK; Jayathilake K; Tunca Z; Göğüş A; Meltzer HY
    J Clin Psychiatry; 2006 Dec; 67(12):1912-9. PubMed ID: 17194269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA; Morrens M; Sabbe BG
    Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind crossover study of the cognitive effects of lorazepam in healthy apolipoprotein E (APOE)-epsilon4 carriers.
    Stonnington CM; Snyder PJ; Hentz JG; Reiman EM; Caselli RJ
    J Clin Psychiatry; 2009 Oct; 70(10):1379-84. PubMed ID: 19573495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clozapine in patients with chronic schizophrenia: serum level, EEG and memory performance.
    Adler G; Grieshaber S; Faude V; Thebaldi B; Dressing H
    Pharmacopsychiatry; 2002 Sep; 35(5):190-4. PubMed ID: 12237790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioreceptor assay of neuroleptics in refractory chronic schizophrenic patients.
    Lindenmayer JP; Smith D; Katz I
    J Clin Psychiatry; 1984 Mar; 45(3):117-9. PubMed ID: 6142035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs with anticholinergic properties as a risk factor for cognitive impairment in elderly people: a population-based study.
    Cancelli I; Gigli GL; Piani A; Zanchettin B; Janes F; Rinaldi A; Valente M
    J Clin Psychopharmacol; 2008 Dec; 28(6):654-9. PubMed ID: 19011434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute extrapyramidal side effects: serum levels of neuroleptics and anticholinergics.
    Tune L; Coyle JT
    Psychopharmacology (Berl); 1981; 75(1):9-15. PubMed ID: 6117922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of anticholinergic drugs in treatment of acute extrapyramidal side effects.
    Tune L; Coyle JT
    Arch Gen Psychiatry; 1980 Mar; 37(3):293-7. PubMed ID: 6102457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia.
    Mori K; Nagao M; Yamashita H; Morinobu S; Yamawaki S
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jul; 28(4):659-65. PubMed ID: 15276691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum neuroleptic and anticholinergic activity in relationship to cognitive toxicity of antiparkinsonian agents in schizophrenic patients.
    Hitri A; Craft RB; Fallon J; Sethi R; Sinha D
    Psychopharmacol Bull; 1987; 23(1):33-7. PubMed ID: 2885890
    [No Abstract]   [Full Text] [Related]  

  • 17. The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia.
    Vinogradov S; Fisher M; Warm H; Holland C; Kirshner MA; Pollock BG
    Am J Psychiatry; 2009 Sep; 166(9):1055-62. PubMed ID: 19570929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EpiTrack: tracking cognitive side effects of medication on attention and executive functions in patients with epilepsy.
    Lutz MT; Helmstaedter C
    Epilepsy Behav; 2005 Dec; 7(4):708-14. PubMed ID: 16266826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Replacement of chronically administered anticholinergic drugs by amantadine in outpatient management of chronic schizophrenia.
    McEvoy JP; McCue M; Freter S
    Clin Ther; 1987; 9(4):429-33. PubMed ID: 2886223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive functioning related to quality of life in schizophrenia.
    Matsui M; Sumiyoshi T; Arai H; Higuchi Y; Kurachi M
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):280-7. PubMed ID: 17884266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.